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Abstract 
 Objective:  To assess patient perceptions of a North Carolina community pharmacy-based warfarin monitoring service.  Methods: 
Prospective study of patients 18 years of age and older, who filled a prescription for warfarin, in one of five Raleigh area community 
pharmacies, between May 1, 2010 and October 31, 2010.  A 14 item survey, along with a self-addressed stamped envelope, was 
mailed to 330 identified patients. The survey inquired about details of current anticoagulation monitoring services, interest in utilizing 
a local community pharmacy for this service, and confidence in a pharmacist-managed program.  Results:  26% of surveys were 
returned. 48% of surveyed individuals responded that they would be interested in having their warfarin monitoring performed by a 
trained pharmacist in a community pharmacy setting. Conclusion:  Many participants responded that the community pharmacy 
would be more convenient than or as convenient as their current location.  This may be a new clinical service that could be offered in 
certain community pharmacies.   
 
 
Introduction 
Warfarin provides an effective pharmacological option for the 
prevention and/or treatment of thromboembolus due to 
multiple conditions
 1
.  Although warfarin offers many 
benefits, it also has potential risks and adverse effects 
associated with its use, with bleeding as the major risk of 
concern.  This risk can be minimized with proper 
administration, monitoring, and patient education
2
.    
 
The CHEST guidelines recommend the use of a “systematic 
process” involving a knowledgeable provider who can offer 
reliable monitoring, structured follow-up, and appropriate 
patient education
1
.  Historically, this process has been driven 
by the patient’s physician or primary care provider.  However, 
trained pharmacists are qualified individuals to facilitate this  
process, as they are the “medication experts”, with vast 
experience in managing medications and providing patient 
education.  Recently, there has been an increasing movement 
toward more clinical involvement within the healthcare team 
and pharmacists have been effectively managing 
anticoagulation services for many years.
2,3,4,5,6
.    Positive 
benefits seen with pharmacist-directed management include:  
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maintaining goal INR range, decreased warfarin-related 
hospital admissions, decreased length of stay, decreased 
number of major thromboembolic events, increased patient 
education, and improved compliance
2,6
.   The usual settings in 
which pharmacists manage anticoagulation services include 
community hospitals, ambulatory care clinics, and physician 
offices
3
. 
 
The community pharmacy offers an accessible, convenient 
location for patients to receive clinical services.  Patients 
often visit the pharmacy at least once monthly, if not more 
frequently, to pick up prescriptions.  Despite the suitability of 
community pharmacies for such services, there are 
surprisingly few that have ventured into providing 
anticoagulation services, such as warfarin monitoring.  Within 
the state of North Carolina, to the best of our knowledge, 
there are no well-defined on-site warfarin monitoring 
services performed by community pharmacies.  It can be 
difficult for pharmacists to provide such services as there are 
often state-specific limitations or restrictions regarding 
pharmacist-implemented therapy changes.  However, North 
Carolina allows pharmacists to become Clinical Pharmacist 
Practitioners (CPP) with prescribing capabilities under a 
physician collaborative practice agreement
7
.  This provides a 
unique opportunity for a CPP and a physician to jointly 
manage anticoagulation patients in a variety of settings
7
.  
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Kerr Drug is a regional pharmacy chain located throughout 
North Carolina with 76 locations.  For the past 14 years, Kerr 
Drug has been at the forefront of offering clinical pharmacy 
services to patients.  These services include preventative 
screenings, disease state management, American Diabetes 
Association (ADA) recognized diabetes education, and 
immunizations
8
.  This unique setting presents an excellent 
opportunity to expand and offer additional clinical services 
such as anticoagulation management.  
 
Literature documenting community pharmacy-based 
anticoagulation monitoring clinics is limited; and no studies 
exist evaluating such a service in North Carolina.  A literature 
search revealed a few abstracts looking at prescriber 
perspective on this particular service
9,10,11
.  There also have 
been some abstracts and studies looking at implementation 
in other states; these studies examined the successfulness of 
community pharmacists in managing anticoagulation patients 
(looking at maintenance of goal INR) in more traditional 
settings
 4,5,12
.  However, these did not look specifically at the 
community pharmacy setting.  
 
Objective 
To assess patient perceptions of a North Carolina community 
pharmacy-based warfarin monitoring service.  The purpose of 
this study was to establish if a community pharmacist-
managed warfarin monitoring service would be a viable new 
clinical service for Kerr Drug to pursue. The end goal is to 
provide patients with an accessible, reliable location for 
warfarin monitoring.   
 
Methods  
This was a prospective survey-based study.  To be included, 
patients had to be 18 years of age and older, who had filled a 
prescription for warfarin, Coumadin, or Jantoven between 
May 1, 2010 and October 31, 2010.  Individuals had to be 
patients of one of five Raleigh-area Kerr Drug community 
pharmacies, located within a 15 mile radius of each other.  A 
report of eligible patients was generated from a centralized 
database at the Kerr Drug corporate office, according to the 
above parameters.  Institutional review board (IRB) approval 
was obtained. 
 
A prospective 14-question survey (appendix A), along with a 
self-addressed stamped envelope, was mailed to the 
identified patients in December 2010. Informed consent was 
obtained from voluntary participation in the study, as noted 
in the cover letter describing the purpose of the survey 
(appendix B).   Demographics such as age and gender were 
recorded.  The survey inquired if the patient was still 
currently taking warfarin.  If the patient was not taking 
warfarin at the time of survey distribution, the survey ended 
following this question.  If the patient was still taking 
warfarin, he/she was asked to complete the rest of the 
survey. The remainder of the survey inquired about details of 
patients’ current warfarin monitoring services, including 
location, frequency of INR monitoring, out-of-pocket cost, 
and overall satisfaction. The survey also asked about interest 
in utilizing a local community pharmacy for this service, 
confidence in a community pharmacist-managed program, 
and amount willing to pay out-of-pocket.  The survey was 
pilot tested on a small cohort of individuals to check for 
readability/understanding.  
 
An incentive, in the form of the opportunity to be included in 
a drawing for one $20.00 Kerr Drug gift card, was offered to 
patients for return of completed surveys.  Surveys were 
returned to the principal investigator’s office address.  
Results were analyzed using descriptive statistics.  All surveys 
and envelopes were destroyed after the completion of this 
study. 
 
Results 
Of the 330 surveys distributed, 86 completed surveys were 
returned (26% response rate) and analyzed using descriptive 
statistics.  Of the 86 responders, 43/86 (50%) of responders 
were male and 43/86 (50%) of responders were female.  
69/86 (80.2%) of responders were 65 years of age or older.  
70/86 (81.4%) of patients responded that they were currently 
still taking warfarin when the survey was completed. Only 
individuals still currently taking warfarin were asked to 
answer the remaining questions about current 
anticoagulation monitoring location and utilization of a 
community pharmacist-managed monitoring service. Of these 
respondents, 61/70 (87.1%) reported that they had their INR 
checked at least monthly, if not more frequently.  More than 
two-thirds of respondents noted that their INR samples were 
provided via a finger stick.   
 
Confidence 
Approximately half of individuals (48%) indicated that they 
would be interested in having their warfarin monitoring 
service performed by a trained community pharmacist within 
their local community pharmacy.  63% of patients responded 
that they were very confident or confident in a trained 
community pharmacist’s ability to manage their warfarin 
monitoring (figure 1).  
 
Location 
Patients were asked to specify the location of their current 
warfarin monitoring service as physician’s office, 
outpatient/ambulatory care clinic, lab, or other.  68% of 
individuals were having their warfarin monitoring conducted 
at a physician’s office. Individuals that selected other for 
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location specified home monitoring or location at an assisted 
living facility.   
 
Convenience  
Of the 68% of patients currently being monitored in physician 
offices, up to 30% of those patients did not view that setting 
as convenient (figure 2).  When asked about perceived 
convenience of using a community pharmacy as the 
monitoring location, patients indicated it would be more 
convenient than or as convenient as their current location 
(figure 3). 
 
Cost 
43% of patients responded that they would be willing to pay 
something out-of-pocket per visit to have their warfarin 
monitored at the community pharmacy. 74% of those willing 
to pay indicated that they would pay more than $5.00 per 
visit. Almost 12% of individuals, most being 65 years or older, 
that currently pay nothing out-of-pocket responded that they 
would be willing to pay some amount out-of-pocket to have 
this service performed by a trained community pharmacist.  
 
Discussion 
Overall, results were encouraging in regards to a community 
pharmacy-based warfarin monitoring service.  As historically 
warfarin monitoring services have been conducted in 
ambulatory care settings such as community hospitals, 
outpatient clinics, or physician offices, the community 
pharmacy presents as a novel, convenient location for such a 
monitoring service.  Utilizing a community pharmacy for 
warfarin monitoring may also be especially helpful in rural 
areas, where access to healthcare tends to more limited.   
 
The survey was designed to first ascertain information 
regarding the respondent’s current monitoring location.  
Respondents were asked to indicate the type of setting and 
then rate their satisfaction with location and convenience.  
Approximately two-thirds of patients are currently being 
monitored in physician offices and up to one-third of these 
patients do not view this setting as convenient.  This 
represents a target population for individuals for a 
community pharmacy-based warfarin monitoring service.   
 
As community pharmacies can be found on most street 
corners, it was thought that convenient location may play 
into an individual’s decision to use a community pharmacy 
rather than a typical clinic setting, which potentially could 
have accessibility and/or parking issues. Many individuals 
already frequent their local community pharmacy at least 
monthly, if not more often, to pick up prescriptions.  Most 
patients responded that they have their INR tested at least 
once monthly, so being able to pair this appointment with 
their monthly pharmacy visit may be desirable.  With such 
frequent visits and generally easily accessible locations, 
community pharmacies offer an alternative location for such 
clinical services. 
 
The survey was also designed to gain an understanding of 
patient confidence in the trained community pharmacist’s 
ability to provide such a service.  Often, patients do not have 
a full appreciation or understanding of a pharmacist’s ability 
to offer clinical services.  These misconceptions could 
influence a patient’s willingness to utilize a community 
pharmacy as his/her monitoring location.  Based on the 
survey results, patients seem to be open to the idea of 
utilizing a trained pharmacist in a community pharmacy 
setting.  Two-thirds of patients were very confident or 
confident in a trained community pharmacist’s ability to 
manage their warfarin monitoring.  This is a positive 
reflection of patient confidence in pharmacists’ ability to 
provide clinical services.  As the profession advances and 
develops, more emphasis will be placed on the role that 
pharmacists can play in clinical practice.   
 
A warfarin monitoring service is just one example of the many 
innovative clinical services a pharmacist can potentially 
provide. Demonstration programs such as the Asheville 
Project and Project ImPACT have shown that pharmacist-
provided clinical services related to chronic disease states, 
such as diabetes, hyperlipidemia asthma, depression, and 
osteoporosis, can have a positive impact on patient care
13,14
. 
As the face of the profession evolves and healthcare 
continues to change, it will be prudent for community 
pharmacies to start thinking outside of the box in regards to 
services provided.   Community pharmacies could build upon 
the successes of these programs by possibly expanding 
clinical services to include warfarin monitoring.   
 
For the individuals that stated that they would not be 
interested in coming to a community pharmacy for their 
warfarin monitoring services, many stated specific reasons in 
the comments section of the survey.  Some of these patients 
were eligible for in-home monitoring and were unable to 
ambulate to the neighborhood pharmacy.  Another subset of 
respondents indicated that they did not have to pay any 
copay for current monitoring services and would not change 
if that meant having to pay out-of-pocket.  Other factors that 
could have caused individuals to respond as not interested 
include: lack of understanding of pharmacist ability to 
perform clinical services, unclear expectations of how 
prescribers would be involved, satisfaction with current 
setting, and novelty of the idea. 
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Many patients that participated in this survey expressed an 
interest in having warfarin monitoring performed in a 
community pharmacy by a trained pharmacist.  Some 
patients were so excited about the idea that they stopped by 
the principal investigator’s office to express their interest in 
person.  The results of the survey, in regards to patient 
confidence in a community pharmacists’ ability to provide a 
clinical service such as warfarin monitoring, reinforce that 
pharmacists are indeed amongst the most trusted healthcare 
professionals.  We are perceived as the medication experts 
and can be an indispensable member of the healthcare team.   
 
In order to implement this innovative service, the next step in 
the process would be contacting the prescribers to determine 
if they would be agreeable to forming collaborative practice 
agreements, such that the clinical community pharmacist 
could perform the anticoagulation monitoring.  If so, 
interested community pharmacists would need to take the 
steps necessary to establish a collaborative relationship, 
based on the appropriate state laws and regulation.  
Challenges, such as obtaining clinical laboratory improvement 
amendments (CLIA) waivers and establishing appropriate 
billing and documentation, would also need to be addressed 
to ensure long-term feasibility. 
 
Limitations 
As is common with many surveys, not all survey questions 
were answered by all responders.  This meant that analysis 
could not account for 100 percent of responses. This could 
have affected some of the final statistics and numbers. In 
addition, not all of the addresses in the Kerr Drug database 
were accurate, resulting in surveys being returned to sender, 
thereby limiting the available data pool.  
In regards to willingness to pay, survey patients were asked 
how much they would be willing to spend out-of-pocket for 
this particular service per visit.  However, willingness to pay 
can be affected by socioeconomic status which was not 
assessed in this study.  This could potentially impact the 
sustainability of this service if patients in a particular area are 
unwilling or unable to pay.  
 
The survey only asked patients if they would feel comfortable 
having the pharmacist manage their anticoagulation 
monitoring. It did not discuss how dosing changes would be 
addressed and it did not state that the prescriber would 
remain informed of all changes.  Patients may have been 
unclear about how this part of the process would be handled, 
which could have impacted how they responded to questions 
about their confidence in the trained community 
pharmacist’s abilities.  Often, patients are not aware of the 
full scope of clinical services that pharmacists can provide, 
especially in states such as North Carolina, which allow for 
pharmacists to become mid-level practitioners.  This may 
have also impacted how respondents answered these 
questions.    
 
The survey only addressed patient interest and perceptions 
regarding a warfarin monitoring service offered within a 
community pharmacy.  Prescriber perception and acceptance 
was not evaluated.  In order to have a successful monitoring 
service, a collaborative practice agreement would be 
necessary between prescriber and pharmacist.  This would 
require prescriber buy-in for this type of program.  
Additionally, it may be useful to distribute surveys to identify 
if there is an unmet need for anticoagulation monitoring or 
high rates of unattained INR goals in the area. The results of 
these surveys would help determine appropriateness of the 
location for this service. 
 
The survey participants were limited to the Raleigh, North 
Carolina area.  Results may not be the same for different 
areas within North Carolina or within the United States. This 
may limit the applicability to other community pharmacies. 
As previously discussed, not all states have the same 
flexibility regarding collaborative practice.  
 
Conclusions  
Overall, many patients indicated that they were interested in 
utilizing a community pharmacy for their warfarin monitoring 
service.  A majority of patients were very confident or 
confident in a community pharmacist’s ability to manage 
their warfarin monitoring.  Many patients responded that 
their community pharmacy would be more convenient than 
or as convenient as their current location.  Based on the 
results of this survey, anticoagulation may be a potential new 
and innovative clinical service that Kerr Drug or similar 
community pharmacies could explore.  
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Appendices 
Appendix A: Patient Survey (2 pages) 
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Appendix B: Cover letter 
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Figure 1 - Confidence In Having A Trained Community Pharmacist Manage Anticoagulation (n=65) 
 
 
 
 
Figure 2 - Perceptions Regarding Convenience (Accessibility) Of Current Monitoring Location (n=69) 
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Figure 3: Perceptions On Whether The Community Pharmacy Would Be More Convenient (Accessible) Than Current Location 
(n=69) 
 
 
 
 
 
 
 
 
 
 
 
 
